Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04439942
Other study ID # PI2020_843_0047
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 17, 2020
Est. completion date June 1, 2023

Study information

Verified date August 2023
Source Centre Hospitalier Universitaire, Amiens
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Hypertrophic cardiomyopathy (HCM) is a frequent cardiac pathology with an estimated prevalence of 1/500 in France. The main risk factor for sudden death in this pathology is the presence and extent of left ventricular obstruction. To date, the only method allowing a reliable assessment of the extent of left ventricular obstruction is Doppler echocardiography. All patients with HCM should undergo cardiac magnetic resonance imaging (MRI) to confirm the diagnosis and for the detection of fibrosis, but conventional sequences cannot reliably assess the obstruction. 4D-flow MRI provides a complete coverage of an entire volume with the ability to simultaneously measure the outputs of all vessels within that volume in a single sequence and might be able to quantify left ventricular obstruction. The main objective of this study is to compare the quantification of left ventricular obstruction in hypertrophic cardiomyopathy by Doppler echocardiography and 4D flow MRI.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date June 1, 2023
Est. primary completion date June 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years old - Presence of a Hypertrophic cardiomyopathy (HCM) - Affiliation to a social security program - Ability of the subject to understand and express opposition Exclusion Criteria: - Major obesity (> 140 kg) not allowing the patient to enter the tunnel of the machine whose diameter is less than 70cm, - Age < 18, - Person under guardianship or curators, - Pregnant woman, - Allergy to gadolinium chelates, - Claustrophobia, - Any contraindications to MRI

Study Design


Intervention

Other:
cardiac magnetic resonance imaging (MRI)
Cardiac MRI is a mandatory examination for Hypertrophic cardiomyopathy patients as it provides important information about the presence of fibrosis which is also directly associated with sudden cardiac death.

Locations

Country Name City State
France CHU Amiens Amiens

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire, Amiens

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Value of Correlation coefficient between the maximum gradient obtained by 4D flow MRI and the maximum gradient measured by echocardiography. Correlation coefficient assessment between the maximum gradient obtained by 4D flow day 1
Secondary Value of Correlation coefficient between the maximum gradient obtained by 4D flow MRI and the maximum gradient measured by phase-contrast Correlation coefficient assessment between the maximum gradient obtained by 4D flow MRI and the maximum gradient measured by phase-contrast day 1
See also
  Status Clinical Trial Phase
Terminated NCT03249272 - Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve Phase 4
Recruiting NCT03846297 - Optimisation of Decision Making for Defibrillator Implantation in Hypertrophic Cardiomyopathy
Completed NCT02806479 - Hypertrophic Cardiomyopathy Pilot Study
Active, not recruiting NCT01225978 - Refining Information Technology Support for Genetics in Medicine N/A
Completed NCT00001632 - Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease N/A
Completed NCT00001534 - Long Term Effects of Enalapril and Losartan on Genetic Heart Disease N/A
Enrolling by invitation NCT04050579 - OPIE in the Thin Interventricular Septum N/A
Completed NCT03537183 - Will Elevated Left Ventricle Filling Pressures Decrease by a Group Exercise Program in Patients With Hypertrophic CardioMyopathy? N/A
Completed NCT02590809 - Hypertrophic Cardiomyopathy Symptom Release by BX1514M Phase 2
Completed NCT00001396 - Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children With Obstructive Hypertrophic Cardiomyop... Phase 1
Active, not recruiting NCT03723655 - A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM Phase 2/Phase 3
Completed NCT05135871 - Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects Phase 1
Completed NCT04129905 - Assessment of the Relations Between Endothelial and Venous Dysfunctions and Left Ventricular Obstruction in Genetic Hypertrophic Cardiomyopathies N/A
Recruiting NCT03061994 - Metabolomic Study of All-age Cardiomyopathy N/A
Completed NCT02234336 - Assessment of Wall Thickness in Hypertrophic Cardiomyopathy
Recruiting NCT00221832 - Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases N/A
Not yet recruiting NCT03706001 - Efficacy of Psychotherapy for Improving Quality of Life in Patients With Hypertrophic Cardiomyopathy and Depression N/A
Recruiting NCT06169358 - Screening Patients With Fabry Disease in Patients With Hypertrophic Cardiomyopathy or Left Ventricular Hypertrophy
Not yet recruiting NCT04090437 - HCM-AF Ablation With ACUTUS N/A
Completed NCT04402268 - Efficacy of Risk Assessment for Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy